Russotti Gregory sold 2,587 Century Therapeutics shares at $1.93 each, leaving 509,198 shares after the 2026-09-14 transaction. The sale represented about 0.5% of Gregory’s prior holding, giving investors the stated size of the ownership change and the remaining position.
Key Highlights
- The transaction occurred on 14 September 2026 under SEC transaction code S.
- Gregory’s reported ownership after the transaction stood at 509,198 Century Therapeutics shares.
- The sale represented about 0.5% of Gregory’s prior share holding.
Century Therapeutics, Inc. (NASDAQ: IPSC) shares were sold by Russotti Gregory at $1.93 apiece, with 2,587 shares changing hands. The transaction was dated 14 September 2026.
Gregory’s Post-Transaction Holding
Century Therapeutics records the transaction under Russotti Gregory, whose designation appears as “See Remarks.” Gregory’s reported ownership after the transaction was 509,198 shares. That figure represents the stated holding remaining after the sale.
Sale Represents 0.5% of Prior Holding
Transaction code S is associated with the reported sale. The transaction represented about 0.5% of Gregory’s prior share holding.
FAQs
Q: How many Century Therapeutics shares did Russotti Gregory sell?
A: Russotti Gregory sold 2,587 Century Therapeutics shares at $1.93 per share in the reported transaction. The filing dates the sale to 14 September 2026.
Q: What was the ownership impact of the Century Therapeutics share sale?
A: The sale represented about 0.5% of Gregory’s prior share holding. Following the transaction, the filing reported that Gregory owned 509,198 Century Therapeutics shares.
Q: What does transaction code S mean in the Century Therapeutics transaction?
A: The filing identifies transaction code S for Russotti Gregory’s reported sale of 2,587 shares. It does not further describe the meaning of that code.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.